false --09-30 2024 Q2 0001884072 0001884072 2023-10-01 2024-03-31 0001884072 2024-08-23 0001884072 2024-03-31 0001884072 2023-09-30 0001884072 2023-12-31 0001884072 2024-01-01 2024-03-31 0001884072 2023-01-01 2023-03-31 0001884072 2022-10-01 2023-03-31 0001884072 us-gaap:CommonStockMember 2022-09-30 0001884072 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001884072 jewl:SharesToBeIssuedMember 2022-09-30 0001884072 us-gaap:TreasuryStockCommonMember 2022-09-30 0001884072 us-gaap:RetainedEarningsMember 2022-09-30 0001884072 2022-09-30 0001884072 us-gaap:CommonStockMember 2023-09-30 0001884072 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001884072 jewl:SharesToBeIssuedMember 2023-09-30 0001884072 us-gaap:TreasuryStockCommonMember 2023-09-30 0001884072 us-gaap:RetainedEarningsMember 2023-09-30 0001884072 srt:RestatementAdjustmentMember us-gaap:CommonStockMember 2023-09-30 0001884072 srt:RestatementAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001884072 srt:RestatementAdjustmentMember jewl:SharesToBeIssuedMember 2023-09-30 0001884072 srt:RestatementAdjustmentMember us-gaap:TreasuryStockCommonMember 2023-09-30 0001884072 srt:RestatementAdjustmentMember us-gaap:RetainedEarningsMember 2023-09-30 0001884072 srt:RestatementAdjustmentMember 2023-09-30 0001884072 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001884072 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001884072 jewl:SharesToBeIssuedMember 2022-10-01 2022-12-31 0001884072 us-gaap:TreasuryStockCommonMember 2022-10-01 2022-12-31 0001884072 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001884072 2022-10-01 2022-12-31 0001884072 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001884072 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001884072 jewl:SharesToBeIssuedMember 2023-01-01 2023-03-31 0001884072 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001884072 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001884072 jewl:RevisionOfPriorPeriodReclassificationOnWarrantLiabilityMember us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-10-01 0001884072 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001884072 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001884072 jewl:SharesToBeIssuedMember 2023-10-01 2023-12-31 0001884072 us-gaap:TreasuryStockCommonMember 2023-10-01 2023-12-31 0001884072 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001884072 2023-10-01 2023-12-31 0001884072 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001884072 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001884072 jewl:SharesToBeIssuedMember 2024-01-01 2024-03-31 0001884072 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001884072 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001884072 us-gaap:CommonStockMember 2022-12-31 0001884072 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001884072 jewl:SharesToBeIssuedMember 2022-12-31 0001884072 us-gaap:TreasuryStockCommonMember 2022-12-31 0001884072 us-gaap:RetainedEarningsMember 2022-12-31 0001884072 2022-12-31 0001884072 us-gaap:CommonStockMember 2023-03-31 0001884072 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001884072 jewl:SharesToBeIssuedMember 2023-03-31 0001884072 us-gaap:TreasuryStockCommonMember 2023-03-31 0001884072 us-gaap:RetainedEarningsMember 2023-03-31 0001884072 2023-03-31 0001884072 us-gaap:CommonStockMember 2023-12-31 0001884072 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001884072 jewl:SharesToBeIssuedMember 2023-12-31 0001884072 us-gaap:TreasuryStockCommonMember 2023-12-31 0001884072 us-gaap:RetainedEarningsMember 2023-12-31 0001884072 us-gaap:CommonStockMember 2024-03-31 0001884072 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001884072 jewl:SharesToBeIssuedMember 2024-03-31 0001884072 us-gaap:TreasuryStockCommonMember 2024-03-31 0001884072 us-gaap:RetainedEarningsMember 2024-03-31 0001884072 jewl:ScioDiamondTechnologyCorporationMember us-gaap:CommonStockMember 2020-02-03 2020-02-03 0001884072 jewl:ScioDiamondTechnologyCorporationMember 2020-02-03 2020-02-03 0001884072 jewl:ScioDiamondTechnologyCorporationMember 2019-10-17 0001884072 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001884072 us-gaap:FairValueInputsLevel3Member 2023-10-01 2023-12-31 0001884072 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001884072 jewl:ScioDiamondTechnologyCorporationMember 2019-08-07 0001884072 srt:ChiefExecutiveOfficerMember 2023-12-31 0001884072 srt:ChiefExecutiveOfficerMember 2023-09-30 0001884072 srt:ChiefFinancialOfficerMember 2023-12-31 0001884072 srt:ChiefFinancialOfficerMember 2023-09-30 0001884072 srt:ChiefOperatingOfficerMember 2023-12-31 0001884072 srt:ChiefOperatingOfficerMember 2023-09-30 0001884072 us-gaap:SubsequentEventMember 2024-07-01 2024-07-01 0001884072 us-gaap:SubsequentEventMember 2024-07-01 0001884072 us-gaap:SubsequentEventMember 2024-06-27 2024-06-27 0001884072 us-gaap:SubsequentEventMember 2024-06-27 0001884072 us-gaap:SubsequentEventMember 2024-05-17 2024-05-17 0001884072 us-gaap:SubsequentEventMember 2024-05-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

x	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March~~June 3130, 2024

o	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

COMMISSION FILE NUMBER 001-41560

(ADAMAS LOGO)

ADAMAS ONE CORP.

(Exact Name of registrant as specified in its charter)

Nevada		83-1833607
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

17767 N. Perimeter Drive, Suite B115, Scottsdale, AZ		85255
(Address of principal executive offices)		(Zip Code)

(480) 356-8798

(Registrant’s telephone number, including area code)

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock, $0.001 par value		JEWL		The ~~Nasdaq~~OTC ~~Stock market~~Markets, LLC ~~(Nasdaq Capital Market)~~

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ox No xo

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Accelerated filer o Non-accelerated ~~filer~~Filer x Smaller reporting company x Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of August 23, 2024, the issuer had 38,047,648 shares of Common Stock outstanding.

ADAMAS ONE CORP. ~~Table of Contents~~

		Page
PART I	FINANCIAL INFORMATION
Item 1.	Condensed Financial Statements (unaudited)
	Condensed Balance Sheets	3
	Condensed Statements of Operations	4
	Condensed Statements of Stockholders’ Equity (Deficit)	5
	Condensed Statements of Cash Flows	6
	Notes to Condensed Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 4.	Controls and Procedures	19
PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	19
Item 1A.	Risk Factors	20
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3.	Defaults Upon Senior Securities	20
Item 4.	Mine Safety Disclosures	20
Item 5.	Other Information	20
Item 6:	Exhibits	21
SIGNATURES		22

Table of Contents

		Page
PART I	FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)
	Condensed Balance Sheets	3
	Condensed Statements of Operations	4
	Condensed Statements of Stockholders’ Equity (Deficit)	5
	Condensed Statements of Cash Flows	6
	Notes to Condensed Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20
PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	21
Item 5.	Other Information	21
Item 6.	Exhibits	22
SIGNATURES		23

ADAMAS ONE CORP.

CONDENSED BALANCE SHEETS

	At March 31,			At September 30,
	June 30,
	2024			~~2023~~September 30,
	(Unaudited)			2023
ASSETS
Current Assets:
Cash	$	6416,~~123~~102		$	26,088
Accounts receivable, net of allowance		15,218			80,347
Inventory		1,~~487~~333,~~837~~936			1,555,222
Total Current Assets		1,~~567~~365,~~178~~257			1,661,657
Property and Equipment, net		1,~~762~~750,~~211~~440			1,785,753
Non-Current Assets:
Goodwill		5,413,000			5,413,000
Other intangible assets, net		~~390~~372,000			426,000
Right of use assets - operating leases		1531,~~558,245~~704			1,677,628
Investment		1,917,673			1,917,673
Other non-current assets		12,800			12,800
Total non-current assets		119,~~053~~997,~~929~~617			11,232,854
TOTAL ASSETS	$	1211,~~621~~362,~~107~~874		$	12,894,511
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
Current Liabilities:
Accrued liabilities	$	12,~~288~~178,~~267~~616		$	1,015,050
Accrued interest		~~394~~492,~~990~~916			95,197
Due to related party - payroll and related		1,455,468			1,130,074
Due to related party- payroll and related		1,102,619			1,130,074
Assumed liability - asset purchase		457,912			457,912
Notes payable and convertible term notes, net		4,069,925			2,195,708
Warrant liability		-			298,839
Derivative liability		956,891			-
Notes payable and convertible term notes, net		4,265,875			2,195,708
Current portion of operating lease liability		210,780			157,286
Derivative liability		1,100,945			-
Contingent consideration for debt compliance		2,922,280			2,922,280
Current portion of operating lease liability		129,936			157,286
Total Current Liabilities		11,756,513			8,272,346
Contingent consideration for debt compliance related to notes payable		2,922,280			2,922,280
Total Current Liabilities		12,651,098			8,272,346
Long-Term Liabilities:
Operating lease liability, net of current portion		1,370,~~589~~507			1,498,674
Total liabilities		13,127,102			9,771,020
TOTAL LIABILITIES		13,021,605			9,771,020
Stockholders’ Equity (Deficit)
Preferred stock, $0.001 par value, 10,000,000 shares authorized, zero shares issued or outstanding as of March 31, 2024 and September 30, 2023
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued or outstanding as of June 30, 2024 and September 30, 2023
Common stock, $0.001 par value, 100,000,000 shares authorized, 35,052,478 shares issued and outstanding at March 31, 2024 and 27,215,966 shares issued and outstanding at September 30, 2023		35,400			27,564
Common stock, $0.001 par value, 100,000,000 shares authorized 37,892,478 shares issued and outstanding at June 30, 2024 and 27,215,966 shares issued and outstanding at September 30, 2023		38,241			27,564
Treasury stock 350,000 shares, at cost		(1,200,000	)		(1,200,000	)
Shares to be issued- strategic entity		1,179,012			1,527,312
Additional paid-in capital		7172,~~014~~053,~~694~~894			66,372,882
Accumulated deficit		(7173,~~535~~729,~~101~~877	)		(63,604,267	)
Total Stockholders’ Equity (deficit)		(~~505~~1,~~995~~658,730	)		3,123,491
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	12,621,107		$	12,894,511
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	11,362,874		$	12,894,511

The accompanying notes are an integral part of these condensed financial statements.

ADAMAS ONE CORP.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	For The Three Months Ended						For The ~~Six~~Nine Months Ended
	March 31,						March 31,
	June 30,						June 30,
	2024			2023			2024			2023
Net Revenues
Diamond sales	$	11179,~~468~~774		$	~~113~~290,~~931~~938		$	~~231~~411,~~272~~046		$	~~840~~1,~~056~~130,994
Cost of revenues		13,710			45,152			300,480			179,998
Cost of Revenues		161,273			217,844			461,753			397,842
Gross Profit (Loss)		(218,~~242~~501	)		6873,~~779~~094			(6950,~~208~~707	)		~~660~~733,~~058~~152
Operating Expenses
Selling, general and administrative		21,~~000~~523,~~422~~258			34,~~283~~253,~~967~~748			34,~~302~~825,~~307~~565			510,~~845~~099,~~446~~194
Employee salaries and related expenses		1391,~~691,454~~396			1196,~~604,775~~295			2,~~153~~544,~~110~~506			6,~~269~~465,~~590~~885
Depreciation and amortization expense		29,771			98,~~852~~851			5989,~~543~~314			~~197~~296,~~704~~555
Total operating expenses		31,~~721~~944,~~647~~425			4,~~987~~548,~~594~~894			57,~~514~~459,~~960~~385			1216,~~312~~861,~~740~~634
Loss from Operations		(31,~~723~~925,~~889~~924	)		(4,~~918~~475,~~815~~800	)		(57,~~584~~510,~~168~~092	)		(1116,~~652~~128,~~682~~482	)
Other Expenses
Other (Income) and Expenses
Interest expense		331,352			27,132			538,576			2,271,178
Gain on lease termination		(54,384	)		-			(54,384	)		-
Warrant expense		—			—			851,200			—
Interest expense		179,182			62,383			717,758			2,333,561
Financing costs		413,793			—			519,855			—
Warrant expense		-			-			851,200			-
Change in fair value of derivative liability		433,512			—			437,036			—
Finance costs		571,680			-			1,091,535			-
Total Other Expenses		1,178,657			27,132			2,346,667			2,271,178
Change in fair value of derivative liability		(427,626	)		-			9,410			-
Loss before income taxes		(4,902,546	)		(4,945,947	)		(7,930,835	)		(13,923,860	)
Total Other Expenses		268,852			62,383			2,615,519			2,333,561
Provision for income taxes		—			—			—			—
Loss before income taxes		(2,194,776	)		(4,538,183	)		(10,125,611	)		(18,462,043	)
Net Loss	$	(4,902,546	)	$	(4,945,947	)	$	(7,930,835	)	$	(13,923,860	)
Provision for income taxes		-			-			-			-
Net Income / (Loss) Per Share
Net Loss	$	(2,194,776	)	$	(4,538,183	)	$	(10,125,611	)	$	(18,462,043	)
Net Loss Per Share
Basic and diluted
Weighted average number of shares outstanding		3230,~~157~~579,~~323~~649			2123,~~861~~668,~~035~~106			3029,~~060~~276,~~685~~159			1920,~~616~~966,~~301~~902
Loss per share-basic and diluted	$	(0.1507	)	$	(0.2319	)	$	(0.2635	)	$	(0.7188	)

The accompanying notes are an integral part of these condensed financial statements.

ADAMAS ONE CORP.

CONDENSED STATEMENTS OF STOCKHOLDERS ’ EQUITY (DEFICIT)

(Unaudited)

						Additional
	Common Stock					Paid-In		Shares	~~Shares~~		~~Treasury~~	Treasury			~~Accumulated~~	Accumulated
	Shares Outstanding			Par Value		Capital		To Be Issued	~~To Be Issued~~		~~Stock~~	Stock			~~(Deficit)~~	(Deficit)			~~Total~~	Total
Balance at September 30, 2022		16,369,423		$	16,369	$	36,511,950	$	—-		$	—$	-		$	~~(41,315,731~~$	)(41,060,328	)	$	~~(4,787,412~~$	)(4,532,009	)
Adjustment to opening balance		—			—		—		—			—				255,403				255,403
Common stock issued conversion of notes and accrued interest		1,813,845			1,814		6,266,585		-				-				-				6,268,399
Balance at October 01, 2022		16,369,423		$	16,369	$	36,511,950	$	—		$	—			$	(41,060,328	)		$	(4,532,009	)
Common stock issued to employees		920,000			920		3,679,080		-				-				-				3,680,000
Common stock issued for conversion of notes and accrued interest		1,813,845			1,814		6,266,585		—			—				—				6,268,399
Common stock issued for IPO		2,450,000			2,450		9,130,300		-				-				-				9,132,750
Common stock issued to employees		920,000			920		3,679,080		—			—				—				3,680,000
Warrants issued		-			-		2,038,000		-				-				-				2,308,000
Common stock issued for IPO, net of costs of $1,892,250		2,450,000			2,450		9,130,300		—			—				—				9,132,750
Repurchase of stock		(350,000	)		-		-		-				(1,200,000	)			-				(1,200,000	)
Warrants issued		—			—		2,038,000		—			—				—				2,038,000
Net loss		-			-		-		-				-				(8,977,913	)			(8,977,913	)
Repurchase stock		(350,000	)		—		—					(1,200,000	)			—				(1,200,000	)
Balance at December 31, 2022		21,203,268		$	21,553	$	57,625,915	$	-			$	(1,200,000	)		$	(50,038,241	)		$	6,409,227
Net loss																(8,977,913	)			(8,977,913	)
Common stock issued to employees		225,000			225		772,775		-				-				-				773,000
Balance at December 31, 2022		21,203,268		$	21,553	$	57,625,915	$	—		$	(1,200,000	)		$	(50,038,241	)		$	6,409,227
Common stock issued for consulting services		632,500			632		1,559,068		-				-				-				1,559,700
Common stock issued to employees		225,000			225		772,775		—			—				—				773,000
Common stock issued for conversion of notes and accrued interest		95,758			95		279,308		-				-				-				279,403
Common stock issued for consulting services		632,500			633		1,559,068		—			—				—				1,559,701
Net loss		-			-		-		-				-				(4,945,947	)			(4,945,947	)
Common shares issued for conversion of notes and accrued interest		95,758			96		279,305		—			—				—				279,401
Balance at March 31, 2023		22,156,526		$	22,505	$	60,237,063	$	-			$	(1,200,000	)		$	(54,984,188	)		$	4,075,380
Net loss																(4,945,947	)			(4,945,947	)
Common stock issued to employees		513,500			513		1,248,303		-				-				-				1,248,816
Balance at March 31, 2023		22,156,526		$	22,506	$	60,237,063	$	—		$	(1,200,000	)		$	(54,984,188	)		$	4,075,381
Common stock issued to board members		75,000			75		246,075		-				-				-				246,150
Balance at September 30, 2023		27,215,966		$	27,564	$	66,372,882	$	1,527,312		$	(1,200,000	)		$	(63,604,267	)		$	3,123,491
Common shares issued for consulting		2,385,000			2,385		2,421,444		-				-				-				2,423,829
Adjustment to opening balance		—			—		298,839		—			—				—				298,839
Common stock issued for conversion of notes and accrued interest		105,000			105		206,335		-				-				-				206,440
Balance at October 01, 2023		27,215,966			28,564	$	66,671,721	$	1,527,312		$	(1,200,000	)		$	(63,604,267	)		$	3,422,330
Common stock issued for ownership in strategic entity		207,792			208		163,699		-				-				-				163,907
Common stock issued to employees		178,215			178		105,860		—			—				—				106,038
Common stock issued for inducement to lenders		225,000			225		240,482		-				-				-				240,707
Common stock issued for consulting services		566,964			567		463,464		—			—				—				464,031
Net loss		-			-		-		-				-			$	(4,538,183	)		$	(4,538,183	)
Common stock issued to board members		80,000			80		43,620		—			—				—				43,700
Balance at June 30, 2023		25,667,818		$	26,015	$	64,763,401	$	-			$	(1,200,000	)		$	(59,522,371	)		$	4,067,045
Common stock issued for inducement to lenders		180,000			180		91,020		—			—				—				91,200
Balance at September 30, 2023		27,215,966		$	27,564	$	66,372,882	$	1,527,312			$	(1,200,000	)		$	(63,604,267	)		$	3,123,491
Common stock issued for conversion of note and accrued interest		30,000			30		16,920		—			—				—				16,950
Adjustment to opening balance		-			-		298,839		-				-				-				298,839
Common stock issued for ownership in strategic entity		300,000			300		179,700		(180,000	)		—				—				—
Balance at October 01, 2023		27,215,966		$	28,564	$	66,671,721	$	1,527,312			$	(1,200,000	)		$	(63,604,267	)		$	3,422,330
Common stock issued from sale of treasury stock		18,000			18		24,982		—			—				—				25,000
Common stock issued to employees		178,215			178		105,860		-				-				-				106,038
Net loss																(3,028,288	)			(3,028,288	)
Common stock issued for consulting services		566,964			567		463,464		-				-				-				464,031
Balance at December 31, 2023		28,569,145		$	28,917	$	67,597,287	$	1,347,312		$	(1,200,000	)		$	(66,632,555	)		$	1,140,961
Common stock issued to board members		80,000			80		43,620		-				-				-				43,700
Common Stock issued to employees		2,450,000			2,450		1,397,800		—			—				—				1,400,250
Common stock issued for inducement to lenders		180,000			180		91,020		-				-				-				91,200
Common Stock issued for consulting		2,010,000			2,010		819,920		—			—				—				821,930
Common stock issued for ownership in strategic entity		300,000			300		179,700		(180,000	)			-				-				-
Common stock issued to board members		20,000			20		11,880		—			—				—				11,900
Common stock issued for conversion of notes and accrued interest		30,000			30		16,920		-				-				-				16,950
Common stock issued for the conversion of warrants		1,330,000			1,330		849,870		—			—				—				851,200
Common stock issued from sale of treasury stock		18,000			18		24,982		-				-				-				25,000
Common stock issued for conversion of note and accrued interest		210,000			210		82,900		—			—				—				83,110
Net loss		-			-		-		-				-				(3,028,288	)			(3,028,288	)
Common stock issued for inducement to lenders		163,333			163		87,037		—			—				—				87,200
Balance at December 31, 2023		28,569,145		$	28,917	$	67,597,287	$	1,347,312			$	(1,200,000	)		$	(66,632,555	)		$	1,140,961
Common stock issued for ownership in strategic entity		300,000			300		168,000		(168,300	)		—				—				—
Common stock issued to employees		2,450,000			2,450		1,397,800		-				-				-				1,400,250
Net loss															$	(4,902,546	)		$	(4,902,546	)
Common stock issued for consulting services		2,010,000			2,010		819,920		-				-				-				821,930
Balance at March 31, 2024		35,052,478		$	35,400	$	71,014,694	$	1,179,012		$	(1,200,000	)		$	(71,535,101	)		$	(505,995	)
Common stock issued to board members		20,000			20		11,880		-				-				-				11,900
Common stock issued for the conversion of warrants		1,330,000			1,330		849,870		-				-				-				851,200
Common stock issued for conversion of notes and accrued interest		210,000			210		82,900		-				-				-				83,110
Common stock issued for inducement to lenders		163,333			163		87,037		-				-				-				87,200
Common stock issued for ownership in strategic entity		300,000			300		168,000		(168,300	)			-				-				-
Net loss		-			-		-		-				-				(4,902,546	)			(4,902,546	)
Balance at March 31, 2024		35,052,478		$	35,401	$	71,014,694	$	1,179,012			$	(1,200,000	)		$	(71,535,101	)		$	(505,994	)
Common stock issued to board members		20,000			20		7,580		-				-				-				7,600
Common stock issued for consulting services		2,540,000			2,540		955,145		-				-				-				957,685
Common stock issued for inducement to lenders		150,000			150		41,300		-				-				-				41,450
Common stock issued for conversion of notes and accrued interest		130,000			130		35,175		-				-				-				35,305
Net loss		-			-		-		-				-				(2,194,776	)			(2,194,776	)
Balance at June 30, 2024		37,892,478		$	38,241	$	72,053,894	$	1,179,012			$	(1,200,000	)		$	(73,729,877	)		$	(1,658,730	)

The accompanying notes are an integral part of these condensed financial statements.

ADAMAS ONE CORP. CONDENSED STATEMENTS OF CASH FLOWS ~~For The Six Months Ended March 31,~~ (Unaudited)

	For The Nine Months Ended
	June 30,
	2024			2023
OPERATING ACTIVITIES
Net loss	$	(710,~~930~~125,~~835~~611	)	$	(1318,~~923~~462,~~860~~043	)
Adjustments to reconcile net loss to net cash provided by operations:					—
Adjustments to reconcile net loss to net cash used in operations:
Stock issued to employees		1,506,288			6,012,700
Stock to employees		1,506,288			9,931,494
Stock issued for board member services		55,600			—
Stock issued board member services		63,200			-
Stock issued to consultants		12,~~285~~243,~~961~~646			—-
Stock issued for loan inducement		~~178~~219,~~400~~850			—240,707
Inventory reserve		113,243			—
Stock issued for conversion of debt and interest		—			137,798
Warrants issued for conversion		851,200			2,038,000
Depreciation and amortization		5989,~~543~~314			~~197~~296,~~704~~555
Allowance for doubtful accounts		(15,151	)		721,~~600~~300,000
Derivative liability		~~519~~1,~~855~~100,945			—-
Change in fair value of derivative liability		~~437,036~~			—
Changes in assets and liabilities
Changes in assets and liabilities:
Accounts receivable		80,~~280~~279			(~~189~~368,~~483~~402	)
Inventory		~~(45~~221,~~858~~286	)		(~~836~~1,~~310~~087,225	)
Accrued liabilities		273,218			1,921,402
Other current assets		-			(34,546	)
Accrued interest		316,743			(351,025	)
Accrued liabilities		1,200,892			2,666,089
Accrued payroll and related liabilities		(325,394	)		824,538
Investment		-			(1,917,673	)
Right of use assets- operating leases, net		44,792			3,893
Accrued interest		533,084			13,061
Total Adjustments to reconcile net loss to net cash used in operations		5,986,543			9,831,817
Accrued payroll and related liabilities		(64,780	)		(705,074	)
Net cash used in operating activities		(1,944,291	)		(4,092,043	)
Right of use assets - operating leases, net		(9,594	)		(12,089	)
Total adjustments to reconcile net loss to net cash used in operations		8,020,458			12,360,897
Net cash used in operating activities		(2,105,153	)		(6,101,146	)
INVESTING ACTIVITIES
Property & equipment		—			(1,464,600	)
Purchase of property & equipment		-			(1,464,600	)
Net cash used in investing activities		—-			(1,464,600	)
FINANCING ACTIVITIES
Notes payable proceeds		12,~~986~~099,~~411~~252			—754,200
Payments on note payables		(29,085	)		~~(1,000,000~~-	)
Due to related party		—-			(558,658	)
Purchase of treasury stock		—-			(1,200,000	)
Cash from sale of stock, net of costs		25,000			9,132,750
Cash from stock sale, net of costs		25,000			9,132,750
Net cash provided by financing activities		12,~~982~~095,~~326~~167			68,~~374~~128,~~092~~292
Net cash increase for the period	$	38,035		$	817,449
Net cash increase (decrease) for the period		(9,986	)		562,546
Cash, beginning of period		26,088			88,235
Cash, end of the period	$	6416,~~123~~102		$	~~905~~650,~~684~~781
Non-cash investing and financing activities are as follows:
Conversion of debt to equity	$	100,060		$	6,155,000
Stock for interest	$	-		$	169,756
Investment	$	348,300		$	—
Conversion of debt to equity	$	100,060		$	6,554,151
Investment	$	348,300		$	-

The accompanying notes are an integral part of these condensed financial statements.

ADAMAS ONE CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

For the ~~Six~~Nine Months Ended ~~March~~June 3130, 2024 and 2023

NOTE 1 – ORGANIZATION AND BUSINESS ACTIVITY

WeAdamas ~~were~~One Corp. (the “Company”) was incorporated on September 6, 2018, in the state of Nevada for the purpose of acquiring existing technology that would efficiently and effectively produce lab-grown, environmentally friendly, ethically sourced diamonds. On January 31, 2019, we entered into an Amended Asset Purchase Agreement with Scio Diamond Technology Corporation, or Scio, which was subsequently amended February 3, 2020, pursuant to which we acquired substantially all of the assets of Scio, which assets consisted primarily of ~~proprietary~~ proprietary diamond growing chemical reactors, which we refer to as diamond growing machines, patents, and all intellectual property ~~related~~ related thereto, for an aggregate of 1,500,000 shares of our common stock and payment to certain lenders of Scio of an aggregate of $2.1 million in cash. In addition, we agreed to pay one-half of certain other unsecured operational liabilities of Scio. The transaction was approved by a majority of the Scio stockholders voting in person or by proxy at a special meeting of stockholders held commencing on July 12, 2019 and reconvening on August 6, 2019. The transaction closed on October 17, 2019. We recorded the fair value of the assets purchased and liabilities assumed at $8.7 million.

The assets and liabilities were valued using ASC 805, the fair value of assets acquired, and liabilities assumed in a business combination, which requires the measurement of assets acquired and liabilities assumed to be recognized at their acquisition-date fair values.

Since acquiring the assets of Scio, we have continued to further develop the technologies acquired from Scio, and we have begun producing diamonds for fine jewelry and diamond material for industrial uses.

On April 17, 2024, the Company announced the establishment of a Board of Advisors for it’s newly formed Adamas Technologies subsidiary. Adamas Technologies was formed on November 9. 2023 and is responsible for research and development, partnerships and deployment of lab-grown diamond-based solutions for the technology industry. The board consists of Jerry McGuire, the Adamas One Corp. COO and three technology industry veterans. Activity during the quarter has been focused on planning, as the subsidiary intends to take Adamas One Diamond Technology into high-tech industrial markets including semiconductors.

NOTE 2 – GOING CONCERN

The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We incurred a net loss of $710.91 million and used approximately $12.9 1 million of cash in operations for the ~~six~~nine months ended ~~March~~June 3130, 2024. Further information related to a going concern ~~may be obtained in NOTE 2 of~~ the ~~Company’s 2023 audited financial statements for the year ended September 30, 2023, and in the~~ Going Concern Uncertainty paragraph in the Report of Independent Registered Public Accounting Firm, also contained in the above referenced financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for the following year.

We will need additional financing to implement our full business plan and to service our ongoing operations. There can be no assurance ~~that~~ that we will be able to secure any needed funding, or that if such funding is available, the terms or conditions would be acceptable to us. If we are unable to obtain additional financing when it is needed, we will need to restructure our operations and possibly divest all or a portion of our business. We may seek additional capital through a combination of equity offerings and debt financings. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, and could increase our expenses and require that our assets secure such debt. Equity financing, if obtained, could result in dilution to our existing stockholders and/or require such stockholders to waive certain rights and preferences. The ~~condensed~~accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities or any other adjustment that might be necessary should we be unable to continue as a going concern.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Presentation

The accompanying financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for financial information and with the instructions to Form 10-K as promulgated by the Securities and Exchange Commission (the “SEC”). Accordingly, these condensed financial statements include all of the disclosures required by ~~generally~~U.S. ~~accepted~~GAAP ~~accounting principles~~ for complete financial statements.

The Company’s fiscal year begins on October 1 and ends on September 30. Unless otherwise stated, references to particular years, quarters, months and periods refer to the Company’s fiscal years ended in September and the associated quarters, months and periods of those fiscal years.

Reclassification

Certain prior period amounts in the balance sheet, statement of cash flows and accompanying notes have been reclassified to conform to the current period’s presentation.

Cash and Cash Equivalents

For purposes of the ~~statements~~condensed statements of cash flows, we consider highly liquid financial instruments purchased with a maturity of three months or less at the time of purchase to be cash equivalents.

Accounts Receivable

We follow the allowance method of recognizing uncollectible accounts receivable, which recognizes bad debt expense based on a review of the individual accounts outstanding and our prior history of uncollectible accounts receivable. We extend credit based on an evaluation of each customer’s financial condition, and our receivables are generally unsecured. Accounts receivable are stated net of an allowance for doubtful accounts in the balance sheet. We consider accounts past due if outstanding longer than contractual payment terms. We record an allowance based on consideration of a number of factors, including the length of time trade accounts are past due, our previous loss history, the creditworthiness of individual customers, economic conditions affecting specific customer industries, and economic conditions in general. We charge-off accounts receivable after all reasonable collection efforts have been exhausted. We credit payments subsequently received on such receivables to bad debt expense in the period we receive the payment.

As of ~~March~~June 3130, 2024, we had established an allowance of $1.2 million for potentially uncollectible accounts receivable. As of September 30, 2023, we had established an allowance of $1.7 million for potentially uncollectible accounts receivable. We record delinquent finance ~~charges~~ charges on outstanding accounts receivable only if they are collected.

Fair Value Measurement

ASC Topic 820, “Fair Value Measurement”, requires that certain financial instruments be recognized at their fair values at our balance sheet dates. However, other financial instruments, such as debt obligations, are not required to be recognized at their fair values, but GAAP provides an option to elect fair value accounting for these instruments. GAAP requires the disclosure of the fair values of all financial instruments, regardless of whether they are recognized at their fair values or carrying amounts in our balance sheets. For financial instruments recognized at fair value, GAAP requires the disclosure of their fair values by type of instrument, along with other information, including changes in the fair values of certain financial instruments recognized in income or other comprehensive income. For financial instruments not recognized at fair value, the disclosure of their fair values is provided below under “Financial Instruments.”

Nonfinancial assets, such as property, plant and equipment, and nonfinancial liabilities are recognized at their carrying amounts in the Company’s balance sheets. GAAP does not permit nonfinancial assets and liabilities to be remeasured at their fair values. However, GAAP requires the remeasurement of such assets and liabilities to their fair values upon the occurrence of certain events, such as the impairment of property, plant and equipment. In addition, if such an event occurs, GAAP requires the disclosure of the fair value of the asset or liability along with other information, including the gain or loss recognized in income in the period the remeasurement occurred.

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;

Level 2 - Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; or

Level 3 - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

The Company did not have any Level 1 or Level 2 assets and liabilities at ~~March~~June 3130, 2024, or September 30, 2023. The Derivative liabilities are Level 3 fair value measurements.

~~The following is a summary of activity of Level 3 liabilities for the period ended March 31, 2024:~~8

~~Schedule~~The offollowing ~~Fair~~is ~~Value~~a summary of ~~Derivative~~activity ~~Liability~~of Level 3 liabilities for the period ended June 30, 2024:

Balance - September 30, 2023	$	—-
Additions		519,855
Settlements		—-
Change in fair value		437,036
Balance - March 31, 2024	$	956,891
Balance – June 30, 2024	$	956,891

During 2023, the Company issued note payable agreements which contain conversion provisions meeting the definition of a derivative liability which therefore require bifurcation. Further, pursuant to the Company’s contract ordering policy, equity linked instruments subsequently issued resulted in derivative liabilities.

At June ~~March 31~~30, 2024, the Company estimated the fair value of the conversion feature derivatives embedded in the notes payable based on assumptions used in the Cox-Ross-Rubinstein binomial pricing model using the following inputs: the price of the Company’s common stock of $0.4365; risk-free interest rate of 5.50%; expected volatility of the Company’s common stock of 118% based on the historical volatility of the Company’s common stock; exercise price of $0.2586; and terms of three months.

Property and Equipment

We recorded property and equipment purchased at cost. We compute depreciation, after equipment is placed in service, using the straight-line method at rates intended to depreciate the cost of assets over their estimated useful lives, which are generally four to ten years. Upon retirement or sale of property and equipment, we will remove the cost of the disposed assets and related accumulated depreciation from the accounts and any resulting gain or loss is credited or charged to selling, general, and administrative expenses. We charge expenditures for normal repairs and maintenance to expense as incurred. We capitalize additions and expenditures for improving or rebuilding existing assets that extend the useful life. Leasehold improvements made either at the inception of the lease or during the lease term will be amortized over the shorter of their economic lives or the lease term including any renewals that are reasonably assured.

Goodwill

We evaluate goodwill for impairment annually or more frequently when an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. In testing for goodwill impairment, we may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If our qualitative assessment indicates that goodwill impairment is more likely than not, we perform a two-step impairment test. We test goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting unit. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. We estimate the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.

Goodwill represents the excess of fair value over identifiable tangible and intangible net assets acquired in the Scio business combination. Goodwill is not amortized, instead goodwill is reviewed for impairment at least annually, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than it’s carrying value. The goodwill that arose from the Scio asset purchase agreement was independently valued at $5,413,000 as of August 7, 2019. We completed our last annual goodwill ~~impairment~~ impairment test in our fourth quarter for the fiscal year ended September 30, 2023, and as a result of the annual test management determined ~~that~~ that no change was needed to the carrying value of goodwill at ~~September~~June 30, ~~2023~~2024 or as of ~~March~~September 3130, ~~2024~~2023.

Impairment of Long-Lived Assets

We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. No impairment expense was recognized for the ~~six~~nine months ended ~~March~~June 3130, 2024 and 2023.

Revenue Recognition

We generate revenue from the ~~production and~~ sale of diamonds that have been produced or purchased. We recognize revenue according to Accounting Standards Codification 606 – Revenue from Contracts with Customers (“ASC 606”). When the customer obtains control over the promised goods or services, we record revenue in the amount of consideration that we can expect to receive in exchange for those goods. We apply the following five-step model to determine revenue recognition:

●

identification of a contract with a customer;

●

identification of the performance obligations in the contact;

●

determination of the transaction price;

●

allocation of the transaction price to the separate performance obligations; and

●

recognition of revenue when performance obligations are satisfied.

We only apply the five-step model when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception and once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct. Our contracts contain a single performance obligation (delivery of diamonds), and the entire transaction price is allocated to the single performance obligation. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Accordingly, we recognize revenue when the customer obtains control of our product, which typically occurs upon delivery of the product. ~~Our~~Currently, our credit terms are ~~currently that~~ payment is due within 90 days.

Shipping costs consists of fees charged to customers for shipping of sold items by the Company. The performance obligation is to ship the item sold as initiated by the customer. The price is set based on the third-party service provider selected to be used by the customer as well as the speed and location of shipment. Revenue is recognized at a point in time when the shipping label is printed.

Disaggregated Revenue Information

We have no disaggregated revenue to report for the ~~six~~nine months ended ~~March~~June 3130, 2024. Weor ~~continue to have one wholesale customer~~2023.

Advertising Costs

We plan to expense advertising costs as they are incurred. We have incurred no advertising costs to date.

Inventories

~~Inventories~~We state ~~are~~inventories ~~stated~~ at the lower of cost or net realizable value, ~~and~~in ~~consist~~the offollowing ~~various diamond pieces, jewelry pieces, and work in process~~manners. ~~Work-in-process~~We determine ~~and~~cost ~~finished~~using ~~goods included~~ the average cost ofmethod ~~materials,~~on ~~direct~~all ~~labor~~inventory ~~and~~generated ~~overhead.~~by Atour ~~the~~manufacturing ~~closing~~operations ofupon ~~each~~our ~~reporting~~transition ~~period,~~from research ~~the~~and ~~Company~~development ~~evaluates~~in ~~its~~our ~~inventory~~manufacturing infacility ~~order~~ to ~~adjust~~ the ~~inventory~~full ~~for~~production ~~obsolete~~of ~~and~~our ~~slow-moving~~products ~~items~~for sale. We also purchase lab-grown diamonds from a vendor who cuts and polishes the majority of our manufactured diamonds as the vendor has access to other lab-grown diamonds that may supplement the inventory needed by the Company or which may be unique in nature which may appeal to our customers or be used in design of our proprietary jewelry line which is under development. We carry the value of these purchased diamonds at the lower of cost or net realizable value. Included in inventory is work in process which states the average cost method of these items at their state of completion at the condensed balance sheet date. At ~~September~~ June 30, ~~2023~~2024, ~~and~~our ~~March~~inventory 31consisted of finished precious stones in various carat sizes, shapes, and colors that we produced or purchased and work in process. As of June 30, 2024 and September 30, 2023, our inventory consisted primarily of finished precious stones in various carat sizes, shapes, and colors ~~that~~which we produced or ~~purchased~~ and work in process.

Stock-Based Compensation

We account for stock-based compensation at fair value in accordance with Accounting Standards Codification 718 – Compensation – Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all share-based payment awards to employees and directors. On October 01, 2022, we adopted ASU 2022-03, “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.” Accordingly, stock-based compensation is valued using market value of our Common Stock. Stock-based compensation is recognized on a straight-line basis over the vesting periods and forfeitures are recognized in the periods they occur. We account for common stock purchase option awards by estimating the fair value of each option award on the grant date using the Black-Scholes option pricing model that uses assumption and estimates that we believe are reasonable.

We account for stock-based compensation at estimated fair value on the date of grant. There were 2,450,000 shares of common stock granted to employees for one year’s services and fully expensed during the six months ended March 31, 2024. These were valued at an aggregate of $1,400,250.10

We account for stock-based compensation at estimated fair value on the date of grant. There were 12,~~145~~628,~~000~~215 shares of common stock granted to employees for ~~their~~one ~~service~~year’s toservices ~~the~~and ~~Company~~fully expensed during the ~~six~~nine months ended ~~March~~June 3130, ~~2023~~2024. These ~~shares~~ were valued at an aggregate of of $~~4,453,000~~1.5 million.

There were 1,145,000 shares of common stock granted to employees for their service. The price per share was based upon the market closing price on the day of the grant. The grants are fully vested and are recognized upon the date of grant.

Concentrations of Credit Risk

Accounts at banks are insured by the Federal Deposit Insurance Corporation, or the FDIC, up to $250,000. As of ~~March~~June 3130, 2024, our bank account balance ~~was~~did ~~less~~not ~~than~~exceed the federally insured limit.

Income Taxes

We account for income taxes under the asset and liability method in accordance with Accounting Standards Codification 740 - Income Taxes, or ASC 740. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the condensed financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable amounts in years in which those temporary differences are expected to be recovered or settled. If it is more likely than not that some portion or all of a deferred tax asset will not be realized, a valuation allowance is recognized. We reflect changes in recognition or measurement in the period in which the change in judgment occurs. We currently have substantial net operating loss carryforwards. We have recorded a valuation allowance equal to the net deferred tax assets due to the uncertainty of the ultimate realization of the deferred tax assets.

Contingencies

Certain conditions may exist as of the date the condensed financial statements are issued that may result in a loss to us but will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to potential unasserted claims that may result in legal proceedings against us, we evaluate the perceived merits of any claims and the perceived merits of the amount of relief sought or expected to be sought therein and determine if any loss is likely.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability is reasonably estimated, the estimated liability would be accrued in our condensed financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of range of possible loss if determinable and material, would be disclosed. There were no known loss contingencies identified as of ~~March~~June 3130, 2024. (See NOTE 6 below for additional information)

Loss Per Common Share

We calculate basic loss per share using the weighted average number of shares of common stock outstanding during each reporting period. Diluted loss per share includes potentially dilutive financial instruments, such as convertible term notes and related interest. We excluded 1,085,~~577~~217 and ~~823~~883,~~499~~ 132 shares from the weighted average diluted common shares outstanding for the ~~three~~nine months ~~ending~~ended June ~~March 31~~30, 2024 and 2023, respectively, because their inclusion would have been antidilutive. These shares are what would have been issued if the convertible debt, plus accrued interest had been converted for each of the ~~three~~ nine months ended ~~March~~June 3130, 2024 and 2023.

Recently Issued Accounting Pronouncement

Adopted

In February 2016, the FASB issued Accounting Standards Update (“ASC”) 2016-02, Leases (Topic 842). The update improves financial reporting about leasing transactions by requiring a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. We adopted ASU 2016-02 effective October 1, 2022 as required for private companies, given the Company went public in December 2022. We have applied the modified retrospective approach to adopt the new leasing standard. This approach typically applies the new standard to all existing leases existing at the date of initial application and does not require a restatement of comparative periods. We completed the process of aggregating and evaluating lease arrangements and implementing new processes during the fiscal year ended at September 30, 2023. As a result of evaluating the impact of adoption of the ASC on our financial statements we recognized a right-of-use asset and lease liability on our balance sheet for our real estate operating leases. At October 1, 2022 we recognized a right of use asset of $1.4 million, and a lease liability of $1.4 million.

Recently Issued Accounting Pronouncement

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40) (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in US GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2023-09 (“ASU 2023-09”), Income Taxes, which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company'’s disclosures. The new guidance eliminates certain exceptions to the general approach to the income tax accounting model and adds new guidance to reduce the complexity in accounting for income taxes. The guidance will be effective for fiscal years beginning after December 15, 2024 and interim periods within those fiscal years. Early adoption of the amendments is permitted, including adoption in any interim period for public business entities for periods for which financial statements have not yet been issued. We are currently evaluating the impact that the new guidance will have on our condensed financial statements.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326),” which replaces the current incurred loss impairment methodology for most financial assets with the current expected credit loss, or CECL, methodology. ~~This guidance would have to be adopted by October 1, 2023.~~ The series of of new guidance amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. The guidance should be applied on either a prospective transition or modified-retrospective approach depending on the subtopic. The guidance is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact that the new guidance will have on our condensed financial statements, but since we have yet to recognize revenue, adoption is not anticipated to have a material effect.

NOTE 4 – INVENTORIES

As of ~~March~~June 3130, 2024 and September 30, 2023, the inventory balances were ~~composed~~comprised of purchased products carried at the lower of cost or net realizable value, finished products and work in process carried at the value of the costs associated with the manufacturing of the goods. As of ~~March~~June 3130, 2024, finished products and work in process were $1.0.9 million and $0.5 million, respectively. As of September 30, 2023, finished products and work in process were $0.9 million and $0.7 million, respectively. ~~During the six months ended March 31, 2024, we recorded an inventory reserve of $0.1 million.~~ There was no inventory obsolescence in the ~~six~~nine months period ended ~~March~~June 3130, ~~2023~~2024.

As of March 31, 2024 and September 30, 2023, the inventory balances were composed of purchased products carried at the lower of cost or net realizable value, finished products and work in process carried at the value of the costs associated with the manufacturing of the goods. There was no inventory obsolescence in the periods ended December 31, 2023 and September 30, 2022, respectively.

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment are listed net of the related accumulated depreciation as of ~~March~~June 3130, 2024 and September 30, 2023. As of ~~March~~June 3130, 2024~~, the~~. The Company has a deposit on equipment on order in the amount of $1.3 million, which represents approximately 50% of the total purchase price. As the equipment is not yet in service, it is not being depreciated.

Depreciation expense for the three and ~~six~~nine months ended ~~March~~June 3130, 2024 totaled $1118,~~771~~000 and $2335,~~542,~~ 314 respectively. Depreciation expense for the three and ~~six~~nine months ended ~~March~~June 3130, 2023 totaled $8078,~~852~~250 and $~~161~~234,~~704~~750, respectively.

11NOTE 6 – COMMITMENTS AND CONTINGENCIES

NOTE 6 – COMMITMENTS & CONTINGENCIES

Indemnifications

During the normal course of business, we make certain indemnities and commitments under which we may be required to make payments in relation to certain transactions. These may include (i) indemnities to vendors and service providers pertaining to claims based on negligence or willful misconduct; and (ii) indemnities involving the representations and warranties in certain contracts. In addition, under our bylaws we are committed to our directors and officers for providing for payments upon the occurrence of certain prescribed events. The majority of these indemnities and commitments do not provide for any limitation on the maximum potential for future payments that we could be obligated to make. We have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the estimated fair value of these agreements is minimal. Accordingly, we had no liabilities recorded for these agreements as of ~~March~~June 3130, 2024 and September 30, 2023.

Contingent Consideration

The Company’s contingent consideration liabilities related to certain lenders compliance guidelines are included as a current liability on the Balance Sheet at ~~March~~June 3130, 2024 and included herein.

Leases

As the Company’s leases generally do not provide an implicit discount rate, the Company uses the estimated collateralized incremental borrowing rate based on information available at the lease commencement date in determining the present value of lease payments for use in the calculation of the operating lease liabilities and right-of-use assets. This rate is determined using a portfolio approach based on the risk-adjusted rate of interest and requires estimates and assumptions including credit rating, credit spread, and adjustments for the impact of collateral. The Company believes that this is the rate it would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar lease term. Operating lease liabilities and corresponding right-of-use assets include options to extend lease terms that are reasonably certain of being exercised. The Company does not record a lease liability and corresponding right-of-use asset for leases with terms of 12 months or less, and accounts for lease and non-lease components as a single lease component. The Company'’s lease portfolio is comprised of operating leases with the lease cost recorded on a straight-line basis over the lease term.

We are obligated under a triple-net operating lease for our 6,475 square foot manufacturing facility located in Greenville, South Carolina, which is classified as an operating lease. The terms of the lease require a payment of approximately $10,~~000~~680 per month, which includes an estimate for utilities, taxes, and repairs. This lease expires in August 2028.

~~Our~~We ~~business~~believe ~~plan~~this facility will ~~require~~be ~~additional~~adequate to ~~space,~~meet ~~and we~~our ~~will~~current beneeds ~~making~~based ~~plans~~on tothe ~~expand~~property ~~our~~and ~~building~~equipment ~~footprint~~currently atowned. ~~possible~~On ~~new~~April or1, ~~additional~~2023, ~~locations~~we tohad ~~accommodate~~entered ~~additional~~into ~~manufacturing~~a lease to expand ~~equipment.~~our Asmanufacturing ~~part~~footprint ofin ~~the~~Greenville, ~~initial~~South ~~expansion~~Carolina. ~~discussed~~On ~~above~~April 1. 2024, we ~~have~~terminated ~~entered~~the ~~into a~~ lease ~~for~~in ~~23,485~~a ~~square~~mutual ~~feet~~agreement ofwith ~~additional~~our ~~manufacturing~~former ~~space~~landlord, inas ~~Greenville,~~we ~~South~~reassess ~~Carolina,~~the ~~expiring~~locations infor ~~July~~future ~~2036~~growth. In addition, we have a lease for 3,414 square feet of office space in Scottsdale, Arizona, expiring in September 2024. The office is to facilitate the administration and marketing of expanding the manufacturing aspect of our company as well as to administer increased management anticipated in areas of human resources, finance, accounting, and financial analysis as well as sales and marketing to manage the growth in the production output as a result of the second facility in Greenville, South Carolina. We intend to pay for these improvements using a combination of working capital, new debt financing, and equity offerings.

The weighted average remaining lease term and weighted average discount rate for operating leases were 41.65 years and 8%, respectively. The operating lease cost for the ~~six~~nine months ended ~~March~~June 3130, 2024 was approximately $~~180~~230,000.

The future minimum lease payment required under our leases as of ~~March~~June 3130, 2024 are as follows:

Schedule of future minimum lease payment

2024	$	831,124
2025		131,638
2026		134,929
2027		138,302
2028		129,676
Thereafter		-
Total undiscounted cash flows		617,668
Less: present value discount (5% per annum)		119,756
Total lease liabilities	$	500,443

2024		184,098
2025		296,033
2026		299,324
2027		302,697
2028		295,715
Thereafter		788,787
Total undiscounted cash flows		2,166,654
Less: present value discount (8% per annum)		585,285
Total lease liabilities	$	1,581,369

Employment Agreements

We have entered into five separate employment agreements that provide for stock to be issued annually in varying amounts through fiscal 2025. The price per share to be included in employee stock compensation expense will be based upon the fair market value of the stock on the date of grant. The grants are fully vested, pending the service requirement of continued employment.

Additional Compensation

In addition to the above stock commitments, we have agreed to provide certain executive officers with compensation paid in diamonds. These commitments amount to issuing 9.5 carats of diamonds per month through September 2024 and 2.5 carats of diamonds per month through October 2025. For the three and ~~six~~nine months ended ~~March~~June 3130, 2024 and 2023 this obligation has been accrued at a valuation of $1,000 per carat, which is based on management’s estimate of the market value of the diamonds.

Litigation

During December 2022, we became a party to a class action filing previously between Scio and a class action investor. We have retained outside counsel specifically for this matter and are working with other defendants named in this matter to increase our chance of prevailing. On February 17, 2022 the Company filed a motion to dismiss the class action in concert with Scio which filed a separate motion to dismiss this class action. Our approach will continue to seek a dismissal on all items related to this legal action. We believe the case is without merit and will defend our position vigorously. Based on the Company’s assessment of a favorable decision by the court no liability has been recorded on our balance sheet at ~~March 31~~June 30, 2024.

The Company retained outside counsel and filed a motion to dismiss and joined in Scio’s motion to dismiss on February 17, 2023. Specifically, the Company believes it was mis-joined to the lawsuit and that no claims are adequately pled against it. The Company further contended the court lacked subject matter jurisdiction. The case was re-assigned to Hon. Cristina D. Silva. Judge Silva’s on July 5, 2023. On June 14, 2024, the court ordered additional briefing based on the Company’s motion to dismiss for lack of subject matter jurisdiction. The briefing was to commence on June 28, 2024, however, as a result of the court’s inclination to grant the Company’s motion to dismiss, the Plaintiff stipulated to dismiss the claims against the Company, Mr. Grdina, and Scio’s management and filed a voluntary dismissal of all of the claims as of June 28, 2024.

NOTE 7 – NOTES PAYABLE AND CONVERTIBLE TERM NOTES

On March 5, 2024, we entered into an increasing OID promissory note and a securities purchase agreement with a previous lender, with an original principal balance of $700,000. The securities purchase agreement contained an increasing original issue discount of the following: (i) ten percent (10%) if the Notes are satisfied and paid in full on or before the three-month anniversary of the original issue date, (ii) twenty percent (20%) if the Notes are satisfied and paid in full on or before the six-month anniversary of the original issue date, and (iii) thirty percent (30%) thereafter. The interest rate is 10% annually. The outstanding principal balance as of March 31, 2024 is $700,000 less fees incurred by the Company. The Company incurred $95,000 in prepaid interest and fees.

On February 15, 2024, we entered into a securities purchase agreement with a lender with an original principal balance of $272,500 and an original maturity date 6 months after the effective date. The note contains an interest rate of 8% with final payment and accrued interest due on at maturity along with the outstanding principal balance due on August 15, 2024. The securities purchase agreement contained an original issue discount of $21,800 which is being amortized as interest expense over the turn of the agreement. As an inducement to enter into the note 33,333 shares of the Company’s common stock was issued upon the effective date of this note to the lender. The note also included a 5 year warrant to purchase 16,667 shares of the Company’s common stock at a price of $2.50 per share. The Company determined that the fair value of these warrants at the time the agreement was executed to be $76,403 which is being amortized as interest expense over the term of the agreement. The note does not provide for prepayment or repayment of the principal balance and is required to be repaid according to an agreed upon amortization schedule. The note is convertible in full or part at a rate of $2.00 per share. The note is also convertible in part or in total into common shares of the Company at $2.00 per share. The agreement contains an escrow agreement for 458,751 shares of the Company’s common stock to be reserved by the Company’s transfer agent as collateral for the security of the note. The Company has also pledged the majority of its assets as additional security and as part of a security agreement entered into in conjunction with this securities purchase agreement. The principal balance outstanding on the note at March 31, 2024 was $272,500 and $2,688 in interest.

On December 15, 2023, we entered into a note with a private lender with the original balance of $750,000 plus a loan origination fee of $50,000. The Note has a fixed interest payment at $9,500 per month with a term of six months with the principal payment due on June 15, 2024. The Note has a stock origination fee of 150,000 shares of common stock. As of March 31, 2024 the principle outstanding balance is $800,000.

On October 18, 2023 we entered into a note with a private lender with the original balance of $150,000. The note has a fixed interest rate of 30,000 shares and a maturity date of January 18, 2024. As of March 31, 2024 the principle outstanding balance is $150,000.

On September 14, 2023 we entered into a securities purchase agreement with a lender with an original principal balance of $271,739.13 and an original maturity date 12 months after the effective date. The note contains an interest rate of 8% which is payable according to a schedule of seven monthly amortization payments beginning on March 14, 2024 with final payment and accrued interest due on at maturity along with the outstanding principal balance due on September 14, 2024. The securities purchase agreement contained an original issue discount of $21,739 which is being amortized as interest expense over the turn of the agreement. As an inducement to enter into the note 33,240 shares of the Company’s common stock was issued upon the effective date of this note to the lender. The note also included a 5 year warrant to purchase 16,620 shares of the Company’s common stock at a price of $2.50 per share (“First Warrant”). The Company determined that the fair value of these warrants at the time the agreement was executed to be $13,463 which is being amortized as interest expense over the term of the agreement. A second 5 year warrant to purchase 2,500,000 shares of the Company’s common stock at a price of $.01 per share (“Second Warrant”) was issued to the lender and was viable in the event the Company did not file their quarterly report for the period ending June 30, 2023 by September 13, 2023. The Company determined that the fair value of these warrants at the time the agreement was executed to be $2,025,000 which is being amortized as interest expense over the term of the agreement. The note does not provide for prepayment or repayment of the principal balance and is required to be repaid according to an agreed upon amortization schedule. The note is convertible in full or part at a rate of $2.00 per share. The note is also convertible in part or in total into common shares of the Company at $2.00 per share. The agreement contains an escrow agreement for 3,500,000 shares of the Company’s common stock to be reserved by the Company’s transfer agent as collateral for the security of the note. The Company has also pledged the majority of its assets as additional security and as part of a security agreement entered into in conjunction with this securities purchase agreement. The principal balance outstanding on the note at March 31, 2024 was $271,739.

OnThe Company ~~July~~retained ~~31,~~outside ~~2023,~~counsel weand ~~entered~~filed ~~into~~ a ~~note~~motion ~~with~~to ~~a private~~dismiss ~~lender~~and ~~with~~joined anin ~~original~~Scio’s ~~principal~~motion ~~balance~~to ofdismiss ~~$250~~on February 17,~~000~~ ~~and~~2023. anSpecifically, the ~~original~~Company ~~maturity~~believes ~~date~~it 45was ~~days~~mis-joined ~~after~~to the ~~effective~~lawsuit ~~date~~and that no claims are adequately pled against it. The ~~note contains~~Company afurther ~~fixed~~contended the ~~interest~~court ~~rate~~lacked ofsubject ~~5,000~~matter ~~shares~~jurisdiction. ofThe ~~common~~case ~~stock~~was ~~which~~re-assigned isto ~~payable~~Hon. atCristina ~~maturity~~D. ~~along~~Silva. ~~with~~Judge ~~the~~Silva’s ~~outstanding~~on ~~principal~~July ~~balance~~5, 2023. AsOn anJune ~~inducement~~14, to2024, ~~enter~~the ~~into~~court ~~the~~ordered ~~note~~an ~~25,000~~additional ~~shares~~briefing ofbased on the Company’s ~~common~~motion ~~stock~~to ~~was~~dismiss ~~issued~~for ~~upon~~lack ~~the acceptance~~ of ~~this~~subject ~~note~~matter byjurisdiction. ~~the~~The ~~private~~briefing ~~lender.~~was Onto ~~March~~commence 22on June 28, 2024, anhowever, ~~extension~~as ~~was~~a ~~granted~~result ~~effective as~~ of ~~September~~the ~~30,~~court’s ~~2023,~~inclination ~~with~~to angrant ~~extension~~the ~~until December~~Company’s ~~31,~~motion ~~2024~~to indismiss, ~~return~~the ~~for~~Plaintiff anstipulated ~~interest~~to ~~rate~~dismiss ofthe ~~5,000~~claims ~~shares~~against ofthe ~~common~~Company, ~~stock per week~~Mr. ~~The~~Grdina, ~~principal~~and ~~balance~~Scio’s ~~outstanding~~management onand ~~the~~filed a ~~note~~voluntary atdismissal ~~March 31,~~of ~~2024~~all ~~was~~of ~~$250,000,~~the ~~and~~claims as of ~~March~~June 3128, 2024~~, all interest shares have been issued~~.

OnNOTE ~~June~~7 9,– ~~2023,~~NOTES wePAYABLE ~~entered~~AND ~~into~~CONVERTIBLE aTERM securities purchase agreement with a lender with an original principal balance of $1,635,000 and an original maturity date 12 months after the effective date. The note contains an interest rate of 8% which is payable according to a schedule of seven monthly amortization payments beginning on December 9, 2023 with final payment and accrued interest due on at maturity along with the outstanding principal balance due on June 9, 2024. The securities purchase agreement contained an original issue discount of $180,300 which is being amortized as interest expense over the turn of the agreement. As an inducement to enter into the note 200,000 shares of the Company’s common stock was issued upon the effective date of this note to the lender. The note also included a 5 year warrant to purchase 100,000 shares of the Company’s common stock at a price of $2.50 per share. The Company determined that the fair value of these warrants at the time the agreement was executed to be $76,403 which is being amortized as interest expense over the term of the agreement. The note does not provide for prepayment or repayment of the principal balance and is required to be repaid according to an agreed upon amortization schedule. The note is convertible in full or part at a rate of $2.00 per share. The note is also convertible in part or in total into common shares of the Company at $2.00 per share. The agreement contains an escrow agreement for 2,752,000 shares of the Company’s common stock to be reserved by the Company’s transfer agent as collateral for the security of the note. The Company has also pledged the majority of its assets as additional security and as part of a security agreement entered into in conjunction with this securities purchase agreement. The principal balance outstanding on the note at March 31, 2024 was $1,635,000.NOTES

On June 227, ~~2023~~2024, we entered into a promissory note with a private lender with an original ~~principal~~ balance of $50,000 ~~and~~with ~~an original maturity date 30 days after the effective date. The note has been re-negotiated and has~~ a ~~current~~ maturity date of ~~December~~June 3127, 2025. The ~~note~~Note ~~contains~~ has an interest rate of 1510% ~~which is payable at maturity along~~ with the ~~outstanding~~ principal balance. Asand aninterest ~~inducement~~due toat ~~enter~~maturity. ~~into~~The ~~the note~~Note ~~20,000~~has ~~shares~~a ~~of the Company’s common~~ stock ~~was~~origination ~~issued~~fee ~~upon the acceptance~~ of ~~this note by the private lender. The principal balance outstanding on the note at March 31~~100,000 ~~2024~~shares ~~was~~of ~~$50,000~~common stock.

On May 1817, ~~2023~~2024, we entered into a promissory note with a private lender with an original ~~principal~~ balance of $~~200~~100,000 ~~and~~with ana ~~original~~ maturity date 30 ~~days~~of ~~after~~September ~~the~~17, ~~effective date~~2024. The ~~note~~Note ~~contains~~has an interest rate of 1012% ~~which~~with isthe ~~payable~~principal atbalance ~~maturity~~and ~~along~~interest ~~with~~due ~~the~~at ~~outstanding principal balance~~maturity. AsThe anNote ~~inducement~~has toa ~~enter~~stock ~~into~~origination ~~the~~fee ~~note~~of 10100,000 shares of ~~the Company’s~~ common stock ~~was issued upon the acceptance of this note by the private lender~~. ~~This note and accrued interest was paid in full in July 2023.~~

WeOn March 5, 2024, we entered into ~~have~~an aincreasing OID promissory note ~~with~~and a ~~private~~securities ~~lender,~~purchase ~~dated~~agreement ~~May~~with ~~14,~~a ~~2019~~previous lender, with an original principal balance of $~~100~~700,000. The ~~and~~securities purchase agreement contained an increasing original ~~maturity~~issue ~~date~~ discount of ~~September~~the 5,following: ~~2019.~~(i) ~~The~~ten ~~note~~percent ~~has~~(10%) ~~been~~if ~~re-negotiated~~the onNotes are ~~several~~satisfied ~~occasions~~ and ~~has~~paid ain ~~current~~full ~~maturity~~on ~~date~~or ofbefore ~~December~~the ~~31,~~three-month ~~2024. Accrued~~anniversary ~~interest~~of ~~was~~the ~~capped~~original atissue 46date,~~500~~ ~~shares~~(ii) oftwenty percent (20%) if the ~~Company’s~~Notes are ~~common~~satisfied ~~stock~~and ~~which~~paid ~~were~~in ~~issued~~full toon or before the ~~private~~six-month ~~lender~~anniversary onof ~~November 29~~the original issue date, ~~2023.~~and (iii) thirty percent (30%) thereafter. The ~~note~~interest rate is ~~unsecured~~10% annually. The outstanding principal balance ~~outstanding~~as onof ~~the~~June ~~note~~30, at2024 ~~March~~is 31$700,000 ~~2024~~less ~~and~~fees ~~2023~~incurred ~~was~~by the Company. The Company incurred $7295,~~500~~000 in prepaid interest and fees.

On February 15, 2024, we entered into a securities purchase agreement with a lender with an original principal balance of $272,500 and an original maturity date 6 months after the effective date. The note contains an interest rate of 8% with final payment and accrued interest due on at maturity along with the outstanding principal balance due on August 15, 2024. The securities purchase agreement contained an original issue discount of $21,800 which is being amortized as interest expense over the term of the agreement. As an inducement to enter into the note 33,333 shares of the Company’s common stock was issued upon the effective date of this note to the lender. The note also included a 5 year warrant to purchase 16,667 shares of the Company’s common stock at a price of $2.50 per share. The Company determined that the fair value of these warrants at the time the agreement was executed to be $76,403 which is being amortized as interest expense over the term of the agreement. The note does not provide for prepayment or repayment of the principal balance and is required to be repaid according to an agreed upon amortization schedule. The note is convertible in full or part at a rate of $2.00 per share. The note is also convertible in part or in total into common shares of the Company at $2.00 per share. The agreement contains an escrow agreement for 458,751 shares of the Company’s common stock to be reserved by the Company’s transfer agent as collateral for the security of the note. The Company has also pledged the majority of its assets as additional security and as part of a security agreement entered into in conjunction with this securities purchase agreement. The principal balance outstanding on the note at June 30, 2024 was $272,500 and $2,688 in accrued interest due as of June 30, 2024.

On December 15, 2023, we entered into a note with a private lender with the original balance of $750,000 plus a loan origination fee of $50,000. The Note has a fixed interest payment at $9,500 per month with a term of six months with the principal payment due on June 15, 2024. The Note has a stock origination fee of 150,000 shares of common stock. As of June 30, 2024 the principle outstanding balance is $800,000.

On October 18, 2023 we entered into a note with a private lender with the original balance of $150,000. The note has a fixed interest rate of 30,000 shares and a maturity date of January 18, 2024. As of June 30, 2024 the principle outstanding balance is $150,000.

On July 31, 2023, we entered into a note with a private lender with an original principal balance of $250,000 and an original maturity date 45 days after the effective date. The note contains a fixed interest rate of 5,000 shares of common stock which is payable at maturity along with the outstanding principal balance. As an inducement to enter into the note 25,000 shares of the Company’s common stock was issued upon the acceptance of this note by the private lender. On March 22, 2024, an extension was granted effective as of September 30, 2023, with an extension until December 31, 2024 in return for an interest rate of 5,000 shares of common stock per week. The principal balance outstanding on the note at June 30, 2024 was $250,000, and as of June 30, 2024, all interest shares have been issued.

On June 9, 2023, we entered into a securities purchase agreement with a lender with an original principal balance of $1,635,000 and an original maturity date 12 months after the effective date. The note contains an interest rate of 8% which is payable according to a schedule of seven monthly amortization payments beginning on December 9, 2023 with final payment and accrued interest due on at maturity along with the outstanding principal balance due on June 9, 2024. The securities purchase agreement contained an original issue discount of $180,300 which is being amortized as interest expense over the turn of the agreement. As an inducement to enter into the note 200,000 shares of the Company’s common stock was issued upon the effective date of this note to the lender. The note also included a 5 year warrant to purchase 100,000 shares of the Company’s common stock at a price of $2.50 per share. The Company determined that the fair value of these warrants at the time the agreement was executed to be $76,403 which is being amortized as interest expense over the term of the agreement. The note does not provide for prepayment or repayment of the principal balance and is required to be repaid according to an agreed upon amortization schedule. The note is convertible in full or part at a rate of $2.00 per share. The note is also convertible in part or in total into common shares of the Company at $2.00 per share. The agreement contains an escrow agreement for 2,752,000 shares of the Company’s common stock to be reserved by the Company’s transfer agent as collateral for the security of the note. The Company has also pledged the majority of its assets as additional security and as part of a security agreement entered into in conjunction with this securities purchase agreement. The principal balance outstanding on the note at June 30, 2024 was $1,635,000.

On June 2, 2023, we entered into a note with a private lender with an original principal balance of $50,000 and an original maturity date 30 days after the effective date. The note has been re-negotiated and has a current maturity date of December 31, 2025. The note contains an interest rate of 15% which is payable at maturity along with the outstanding principal balance. As an inducement to enter into the note 20,000 shares of the Company’s common stock was issued upon the acceptance of this note by the private lender. The principal balance outstanding on the note at June 30, 2024 was $50,000.

We have a note with a private lender, dated May 14, 2019, with an original principal balance of $100,000 and an original maturity date of September 5, 2019. The note has been re-negotiated on several occasions and has a current maturity date of December 31, 2024. Accrued interest was capped at 46,500 shares of the Company’s common stock which were issued to the private lender on November 29, 2023. The note is unsecured. The principal balance outstanding on the note at June 30, 2024 was $72,500.

NOTE 8 – CAPITAL STOCK

Our authorized capital consists of 100,000,000 shares of common stock with a par value of $0.001 per share and 10,000,000 shares of preferred stock with a par value of $0.001 per share.

As of ~~March~~June 3130, 2024, and 2023, we had no no shares of preferred stock issued or outstanding.

As of ~~March~~June 3130, 2024, there were 3537,~~052~~892,478 ~~shares~~ shares of common stock issued and outstanding. During the ~~three~~nine months ended ~~March~~June 3130, 2024, we issued 62,~~483~~840,~~333~~000 shares of common stock as follows:

2,~~450~~540,000 shares ~~valued at $1,400,250~~ were ~~granted~~issued tofor ~~employees~~consulting asservices ~~compensation~~valued at $957,685;

20130,000 shares ~~valued~~were atissued ~~$11,900~~for ~~were~~conversion of ~~granted~~notes toand ~~our~~accrued ~~board~~interest ~~of directors~~valued asat ~~compensation~~$35,505;

~~163~~20,~~333~~000 shares ~~were~~valued ~~issued~~at ~~for~~ $877,~~200~~600 ~~for~~were ~~incentive~~ granted to ~~lenders:~~board members for services; and

2150,~~010,~~000 shares ~~valued at $821,930~~ were issued for ~~consulting~~$41,450 ~~services;~~for inducement to lenders.

~~210,000 shares valued at $83,110 were issued for the conversion of notes and accrued interest;~~15

1,330,000 shares valued at $851,200 were issued for the conversion of Warrants; and

300,000 shares valued at $168,300 were issued for ownership in a strategic entity.

NOTE 9 – RELATED PARTY

We have various employment contracts and ~~additional~~ additional compensation agreements with members of the executive team, which are discussed in Note 6 – Commitments and Contingencies.

We also have payroll and related liabilities outstanding as of ~~March~~June 3130, 2024 and September 30, 2023 that are primarily owed to our principal officers.

	March 31, 2024		September 30, 2023
	June 30, 2024			September 30, 2023
CEO- Payroll and related	$	~~631~~733,~~023~~123	$	~~440,254~~$	440,254
CFO- Payroll and related		~~810~~882,~~599~~375		~~675,974~~	675,974
COO- Payroll and related		1329,846		~~13,846~~	13,846
Total due to related Party - payroll and related	$	1,~~455~~102,~~468~~619	$	~~1,130,074~~$	1,130,074

NOTE 10 – INCOME TAXES

We compute income taxes using the asset and liability method in accordance with FASB ASC Topic 740, Income Taxes. Under the asset and liability method, we determine deferred income tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities and measure them using currently enacted tax rates and laws. We provide a valuation allowance for the amount of deferred tax assets that, based on available evidence, are more likely than not to be realized. Realization of our net operating loss carryforward was not reasonably assured as of ~~March~~June 3130, 2024 and September 30, 2023, and we have recorded a related valuation allowance against deferred tax assets in excess of deferred tax liabilities in the accompanying condensed financial statements.

As of ~~March~~June 3130, 2024 and September 30, 2023, we had federal income tax net operating loss carryforwards. We are subject to limitations existing under Internal Revenue Code Section 382 (Change of Control) relating to the availability of the operating loss, therefore utilization of a portion of our net operating loss may be limited in future years.

As of ~~March~~June 3130, 2024 and September 30, 2023 we had no Internal Revenue Service or state tax examinations. Therefore, all periods since inception are subject to audit.

NOTE 11 – SUBSEQUENT EVENTS

On July 01, 2024, we entered into a promissory note with a private lender with the original balance of $50,000 with a maturity date of June 30, 2025. The Note has an interest rate of 10% with the principal balance and interest due maturity date. The Note has a stock origination fee of 75,000 shares of common stock.

On ~~June~~July 2701, 2024, we entered into a ~~promissory note~~letter ~~with~~of aintent ~~private~~(“LOI”) ~~lender~~ with ~~the~~Akhan ~~original~~Semiconductor, ~~balance~~Inc. ofto ~~$50,000~~purchase ~~with~~100% aof ~~maturity~~the ~~date~~assets of ~~June~~Akhan ~~27,~~for ~~2025~~$750,000. ~~The~~This ~~Note~~transaction ~~has an interest rate of 10%~~is ~~with~~still ~~the~~pending ~~principal balance~~ and ~~interest~~the ~~due~~Company ~~maturity~~anticipates ~~date.~~closing ~~The~~to ~~Note~~occur ~~has~~on aor ~~stock~~before ~~origination~~October ~~fee of 100~~30,~~000~~ ~~shares of common stock~~2024.

~~On May~~NOTE ~~17, 2024, we entered into a promissory note with a private lender with the original balance of $100,000 with a maturity date of September 17, 2024. The Note has an interest rate of~~ 12% ~~with~~– ~~the~~ADJUSTMENT ~~principal~~TO ~~balance~~OPENING ~~and~~BALANCE ~~interest~~– ~~due~~STATEMENT ~~maturity~~OF ~~date.~~STOCKHOLDERS ~~The~~EQUITY ~~Note has a stock origination fee of 100,000 shares of common stock.~~(DEFICIT)

~~NOTE~~At September 1230, –2023, ~~ADJUSTMENT~~the TOwarrant ~~OPENING~~fair ~~BALANCE~~value –allocation of $298,839, arising from debt issuance should have been classified as additional ~~STATEMENT~~paid-in OFcapital ~~STOCKHOLDERS~~but ~~EQUITY~~was recorded as a warrant liability. This adjustment is to correctly reclassify the amount to Additional paid-in capital at October 1, 2023. The Statement of Stockholders Equity(Deficit) includes an adjustment to the opening balance of $298,839 for October 1, 2023.

At September 30, 2023, the warrant fair value allocation of $298,839, arising from debt issuance should have been classified as additional paid-in capital but was recorded as a warrant liability. This adjustment is to correctly reclassify the amount to Additional paid-in capital at October 1, 2023. The Statement of Stockholders Equity includes an adjustment to the opening balance of $298,839 for October 1, 2023.

Management determined the prior period financial statements were not materially misstated; therefore, the Company is not required to notify users that they can no longer rely on the prior period financial statements.

Schedule of Adjustment to Prior Period Financial Statement

Opening Balance, additional paid-in capital	$	66,372,882
Adjustment		298,839
Adjusted opening balance as of October 1, 2023	$	66,671,721

1516

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This document contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies, goals and objectives of management for future operations; any statements concerning proposed new products and services or developments thereof; any statements regarding future economic conditions or performance; any statements or belief; and any statements of assumptions underlying any of the foregoing.

Forward looking statements may include the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect,” or “anticipate,” or other similar words, or the negative thereof. These forward-looking statements present our estimates and assumptions only as of the date of this report. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the dates they are made. You should, however, consult further disclosures and risk factors we included in the section titled Risk Factors contained herein.

Overview

We are a high-tech, laboratory grown, diamond company that uses our proprietary technology to produce high-quality, single crystal diamonds and diamond materials through a CVD process, which we refer to as our “Diamond Technology”. Lab-grown diamonds have the exact physical, chemical, and optical properties of the best mined diamonds. Lab-grown diamonds are composed of a pure carbon lattice, just like mined diamonds, and are not considered synthetic or simulant diamonds like cubic zirconia and moissanite. Simulants are other chemical compounds that resemble diamonds but do not possess the same hardness, thermal characteristics, band gap energy, and light reflectivity as diamond, whether mined or lab-grown.

We use our Diamond Technology to produce finished ~~diamonds~~diamond gemstones that we intend to sell wholesale and retail for jewelry and rough unfinished diamond materials that we intend to sell wholesale and retail for industrial uses. We are in the initial phases of commercializing diamonds and diamond materials, and our primary mission is the development of a profitable and sustainable commercial production model for the manufacture and sale of diamonds and diamond materials, which are suitable for known, emerging, and anticipated industrial, technology, and consumer applications.

Since acquiring the Scio assets over three years ago, we have focused our efforts on research and development of improvements to the fundamental CVD process. Like most high-tech manufacturers, the philosophy of continuous improvement is at our core. Our development efforts have focused on commercialization of the diamonds and diamond materials we produce, improvements in our white diamond process, improvements in our diamond seed processes, automation in our machine operation, expansion of our capacity with our existing machines, and improvements in our laser cutting procedures. The guiding principle of these efforts is to provide the highest quality diamonds and diamond materials in a consistent and high-yield manner.

We currently have limited available commercial products and have to date sold minimal diamonds or diamond materials to consumers or commercial buyers. Our current operations, until just recently, have been dedicated to the research and development of our Diamond Technology and the exploration of markets that we may exploit in the future. While we are unable to predict the timing of our entry into any market in the future, we will strive to produce on a large scale high-quality finished and raw diamond materials and to pursue related commercial opportunities.

Results of Operations

The following table presents summarized financial information taken from our statements of operations for the three and six months ended March 31, 2024 compared with the three and six months ended March 31, 2023:

	For The Three Months Ended						For The Nine Months Ended
	June 30,						June 30,
	2024			2023			2024			2023
Net Sales	$	179,774		$	290,938		$	411,046		$	1,130,994
Cost of Revenues		161,273			217,844			461,753			397,842
Gross Margin		18,501			73,094			(50,707	)		733,152

Total Operating Expenses		1,944,425			4,548,894			7,459,385			16,861,634
Loss From Operations		(1,925,924	)		(4,475,800	)		(7,510,092	)		(16,128,482	)
Other Expenses		268,852			62,383			2,615,519			2,333,561
Loss Before Income Taxes	$	(2,194,776	)	$	(4,538,183	)	$	(10,125,611	)	$	(18,462,043	)

	For The Three Months Ended						For The Six Months Ended
	March 31,						March 31,
	2024			2023			2024			2023
Net Sales	$	11,468		$	113,931		$	231,272		$	840,056
Cost of Revenues		13,710			45,152			300,480			179,998
Gross Profit		(2,242	)		68,779			(69,208	)		660,058
Total operating expenses		3,721,647			4,987,594			5,514,960			12,312,740
Loss from Operations		(3,723,889	)		(4,918,815	)		(5,584,168	)		(11,652,682	)
Other expenses
Interest expense		331,352			27,132			538,576			2,271,178
Warrant expense		-			-			851,200			-
Financing costs		413,793			-			519,855			-
Change in fair value of derivative liability		433,512			-			437,036			-
Loss before income taxes	$	(4,902,546	)	$	(4,891,683	)	$	(7,930,835	)	$	(13,923,860	)

The preceding table presents summarized financial information taken from our condensed statements of operations for the three and nine months ended June 30, 2024 and June 30, 2023 respectively.

1617

~~Net~~Components of Results of Operations Net Sales

During the three and ~~six~~nine months ended ~~March~~June 3130, 2024, we had net sales of $11179,~~468~~774 and $~~231~~411,~~272~~046 respectively, compared to $~~113~~290,~~931~~938 and $~~840~~1,~~056~~ 130,994 net sales for the three and ~~six~~nine months ended ~~March 31~~June 30, 2023. We anticipate deriving continuing future revenue from the following business lines:

●

Direct Sales of Diamonds: The sale of diamond gemstones direct to the consumer through our website and the sale of industrial grade diamonds direct to industrial manufacturing companies.

●

Wholesale of Diamonds: The sale of diamonds to wholesalers, distributors, and jewelers.

Cost of ~~Goods Sold~~Revenues

Cost of ~~goods~~revenues ~~sold~~ includes direct costs (parts, material, and labor), indirect manufacturing costs (manufacturing overhead, depreciation, plant operating lease expense, and rent), shipping, lab services, and logistics costs.

Costs of revenues for the three and ~~six~~ nine months ended ~~March~~ 31June 30, 2024, were $13161,~~710~~273 and $~~300~~461,~~480,~~753 respectively. Costs of revenues for the three and ~~six~~nine months ended ~~March~~June 3130, 2023 were $45217,~~152~~ 844 and $~~179~~397,~~998~~842, respectively.

Gross ~~loss~~Profit ~~for the three and six months ended March 31, 2024, were $~~(~~2,242~~Loss) ~~and $(69,208), respectively or a gross loss margin on diamond sales of 19.5% for each of those periods.~~

Gross ~~profit~~Profit (Loss) for the three and nine ~~six~~ months ended ~~March~~June 30, 2024, was $18,500 and $(50,707) respectively with a gross margin on diamond sales of 47% and (12.3)% for each 31of those periods, respectively. Gross Profit (Loss)for the three and nine months ended June 30, 2023, was $6873,~~779~~094 and $~~660~~733,~~058~~152, respectively with a gross profit margin on diamond sales of 6025% and 7965% for each of those periods, respectively.

Research and Development Expense

We conduct research and development activities to enhance existing processes and products and develop new processes and products at our facilities in Greenville, South Carolina, utilizing our personnel and strategic relationships. We expense all costs associated with our research and development efforts through either our cost of goods sold, as they are performed by the same employees who produce our finished product, or through our general and administrative expenses if the product has not been brought to market.

We expect our research and development expenses to increase for the foreseeable future as we continue to invest in research and development activities to achieve our operational and commercial goals.

Operating Expense

Operating expense includes selling, general and administrative expense, employee salaries and related expense and depreciation and amortization expense. Selling, general, and administrative expenses consist primarily of legal and professional, consulting services and all non-personnel-related expenses or depreciation and amortization. Personnel-related expenses consist of salaries, payroll taxes, benefits, and stock-based compensation. Depreciation and amortization expenses are related to the Company’s fixed assets and intangible assets.

Operating expense for the three and nine months ended ~~March 31~~June 30, 2024, included in the ~~statement~~condensed statements of operations was $31.79 million and $7.5 million, respectively, compared to $54.5 million and $16.9 million in the ~~comparison~~prior period. These decreases in operating expenses for both the three- and nine-month periods were generally due to the ~~comparable~~lower ~~prior~~stock compensation expense as a result of a lower valuation based on ~~period~~price of the stock at the time of grant.

We expect our future operating expense to increase for the foreseeable future as we scale headcount and expenses with the growth of our business, build out our manufacturing facilities, refine our production processes, drive for productivity improvements, acquire new and retain existing customers, and incur additional costs as a result of being a public company.

Other Expenses

Interest Expense and Other Costs of Financing

Interest expense consists of interest paid and accrued on our notes payable, promissory notes and the amortization of debt issue costs.

Interest ~~expense~~and ~~was~~other expenses were $ 0.53 million and $2.6 million for the ~~six~~three and nine months ended ~~March~~June 3130, 2024, respectively, compared to ~~the~~$.1 ~~interest~~million ~~expense~~and of $2.23 million ~~for~~ the three- ~~six~~and ~~months~~nine-month ~~ended~~periods ~~March~~of ~~31,~~the ~~2023~~prior year. This ~~decrease in interest expense~~ was due primarily to ~~paydown~~the onhigher ~~outstanding~~costs ~~indebtedness~~associated ~~during~~with new financings and lower overall borrowings for the ~~six~~nine months ended ~~March~~June 3130, ~~2023~~2024, versus the ~~six~~nine months ended ~~March~~ 31June 30, ~~2024~~2023.

Net Loss

Primarily as a result of the above factors we had a net loss of $2.2 million and $10.1 million compared to a net loss of $4.95 million and $18.5 million for the three ~~months~~and nine months ended ~~March~~June 3130, 2024, and ~~March~~June 3130, 2023, respectively.

Liquidity and Capital Resources

As of ~~March~~June 3130, 2024, we had $6416,~~123~~ 102 of cash and cash equivalents, acompared ~~decrease~~to of $3826,~~035~~088 ~~from~~at ~~the prior year ended~~ September 30, 2023.

Changes in cash flows are summarized as follows:

Operating Activities

For the ~~six~~nine months ended ~~March~~June 3130, 2024, net cash used in operating activities totaled approximately $12.91 million. This was primarily the result of a net loss of approximately $10.1 million, increases to our period end accounts accrued liabilities of $1.2 million, an increase in our accrued interest of $0.5 million, a increase in derivative liability of $1.1 million, a decrease with an offset by the benefit of non-cash expenses for employee stock compensation and consultants compensation of $3.7 million and warrants issued for conversion of $0.9 million.

For the ~~six~~nine months ended ~~March~~June 3130, 2023, net cash used in operating activities totaled approximately $46.1 million. This was primarily the result of net loss of approximately $1318.5 million offset by the benefit of non-cash expenses for employee stock compensation of $9.9 million.

Investing Activities

During the ~~six~~nine months ended ~~March~~ ~~31,~~June 30, 2024, ~~and~~we ~~2023~~used ~~net~~no cash ~~used~~for in investing activities. ~~related~~During tothe ~~purchases~~nine ofmonths ~~machinery~~ended ~~and~~June ~~equipment~~30, ~~was~~2023, ~~approximately~~we $0used ~~and~~ $1.5 million, ~~respectively~~for investing activities related to purchase of property and equipment.

Financing Activities

During the ~~six~~nine months ended ~~March~~ ~~31,~~June 30, 2024 ~~and 2023~~, net cash provided by financing activities was approximately $12.91 million. ~~and~~This ~~$6.4~~was ~~million~~primarily ~~respectively~~the result of additional borrowings.

During the nine months ended June 30, 2023, net cash provided by financing activities was $8.1 million. This was the net effect of $9.1 million we received as net proceeds from our IPO which closed on December 14, 2022 offset by $0.6 million used to reduce related party notes and $1.2 million to acquire treasury stock during the nine months ended June 30, 2023.

These conditions raise substantial doubt about our ability to continue as a going concern for the ensuing year. Our independent auditors have added an explanatory paragraph in their audit opinion in regard to this uncertainty and can be found in the Company’s Annual Form 10K filing with the Securities and Exchange Commission.

Satisfaction of our Cash Obligations for the Next 12 Months

Our IPO which closed on December 14, 2022, gave us gross proceeds of $11.0 million before direct IPO expenses and fees associated with underwriting. These funds along with the ability to obtain additional capital through additional equity and/or debt financing are anticipated to meet our operating needs. We are not currently generating sufficient revenue to meet operating needs. In the event we cannot obtain additional capital to pursue our strategic plan, however, this would materially impact our ability to continue as a going concern.

Since inception, we have financed cash flow requirements through debt financing and the private issuance of common stock for cash and services along with advances from our CEO as well as our CEO and CFO deferring significant compensation and benefits that were earned under their respective employment contracts. If we continue to experience cash flow deficiencies, we would be required to obtain additional financing to fund operations through private common stock offerings and debt borrowings to the extent necessary to provide working capital. However, there is no assurance we would be able to obtain such financing on commercially reasonable terms, if at all.

We intend to implement and successfully execute our business and marketing strategy, continue to develop, and upgrade technology and products, respond to competitive developments, and attract, retain, and motivate qualified personnel. There can be no assurance that we will be successful in addressing such risks, and the failure to do so can have a material adverse effect on our business prospects, financial condition, and results of operations.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

Critical Accounting Policies

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and ~~the~~ the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in preparing the condensed financial statements include the valuation of allowances for doubtful accounts, valuation of deferred tax assets, inventories, useful lives of assets, goodwill, intangible assets, and stock-based compensation. A summary of our critical accounting policies is included in our Annual Report on Form 10-K for the year ended September 30, 2023, under “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” There have been no significant changes to these policies during the ~~six~~nine months ended ~~March~~June 3130, 2024. For disclosure regarding recent accounting pronouncements and the anticipated impact they will have on our operations, please refer to Note 32 to the ~~condensed~~ financial statements included in our Annual Report on Form 10-K for the year ended September 30, 2023.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of ~~March~~June 3130, 2024. Based on the evaluation of these disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded our disclosure controls and procedures were not effective. Our controls were ineffective due to the size of the Company and available resources. There are limited personnel to assist with the accounting and financial reporting function, which results in: (i) a lack of segregation of duties and (ii) controls that may not be adequately designed or operating effectively. Despite the existence of material weaknesses, the Company believes the financial information presented herein is materially correct and fairly presents the financial position and operating results of the ~~three~~nine months ended ~~March 31~~June 30, 2024, and 2023 in accordance with GAAP.

Changes in internal controls

There were no changes in our internal control over financial reporting, as defined in Rule 13a-15(f) promulgated under the Exchange Act, during the quarterly period from ~~January~~ April 1, ~~2024~~2023 to ~~March~~June 3130, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

~~PART II - OTHER INFORMATION~~20

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are involved in or subject to, or may become involved in or subject to, routine litigation, claims, disputes, proceedings, and investigations in the ordinary course of business. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position, results of operations or cash flows. We record accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated.

On January 10, 2023, the Company was joined as a defendant to an existing lawsuit in the United States District Court for the District of Nevada (case no. 2:22-cv-00256) between Theodorus Strous, a shareholder of Scio Diamond Technology Corp. (“Scio”), and Scio executives, brought as a proposed derivative shareholder class action. The second amended complaint added the Company and John G. Grdina as defendants, expanding the claim to assert a proposed derivative shareholder class action against the Company as well as Scio.

Please reference the Contingencies section of Note 3 of our Condensed Financial Statements for additional disclosure.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The authorized capital of the Company is 100,000,000 shares of Common Stock with a par value of $0.001 per share and 10,000,000 shares of Preferred Stock with a $0.001 par value per share.

There were no unregistered sales of ~~the~~ the Company’s equity securities during the quarter ended ~~March~~June 3130, 2024 that were not previously reported in a Current Report on ~~Form~~ Form 8-K except as follows:

2,~~450~~540,000 shares ~~valued at $1,400,250~~ were ~~granted~~issued tofor ~~employees~~consulting asservices ~~compensation~~valued at $957,685;

20130,000 shares ~~valued~~were atissued ~~$11,900~~for ~~were~~conversion ~~granted~~of tonotes ~~our~~and ~~board~~accrued interest ofvalued ~~directors as~~at ~~compensation~~$35,505;

~~163~~20,~~333~~000 shares ~~were~~valued ~~issued~~at ~~for~~ $877,~~200 for~~600 ~~incentive~~were granted to ~~lenders:~~board members for services; and

2150,~~010,~~000 shares ~~valued~~were atissued for $~~821~~41,~~930~~450 ~~were issued~~ for ~~consulting~~inducement ~~services;~~to lenders.

210,000 shares valued at $83,110 were issued for the conversion of notes and accrued interest;

1,330,000 shares valued at $851,200 were issued for the conversion of Warrants; and

300,000 shares valued at $168,300 were issued for ownership in a strategic entity.

The previously mentioned securities were issued in reliance on the exemptions from registration under the Securities Act in Section 4(a)(2) of the Securities Act and/or Regulation D thereunder.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable

ITEM 5. OTHER INFORMATION

None

2021

ITEM 6. EXHIBITS

Exhibit No.	Exhibit	~~Exhibit~~
31.1*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for John G. Grdina.	~~Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for John G. Grdina.~~
31.2*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Steven Staehr.	~~Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Steven Staehr.~~
32.1**	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for John G. Grdina.	~~Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for John G. Grdina.~~
32.2**	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for Steven Staehr.	~~Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for Steven Staehr.~~
101.INS*		Inline XBRL Instance Document
99.1*	Temporary Hardship Exemption
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

101.INS***	Inline XBRL Instance Document
101.SCH***	Inline XBRL Taxonomy Extension Schema Document
101.CAL***	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB***	Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE***	Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF***	Inline XBRL Taxonomy Extension Definition Linkbase Document
104***	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Filed Herewith.

** Furnished Herewith. *** To be furnished by amendment per Temporary Hardship Exemption under Regulation S-T.

2122

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ADAMAS ONE CORP.

August 26, 2024	By:	/s/ John G. Grdina
October 15, 2024	By:	/s/ John G. Grdina
		John G. Grdina
		Chief Executive Officer

ADAMAS ONE CORP.

August 26, 2024	By:	/s/ Steven Staehr
October 15, 2024	By:	/s/ Steven Staehr
		Steven Staehr
		Chief Financial Officer

2223

Filing Compare · Adamas One Corp.